Additionally, the subgroup analysis of PDAC patients suggested that CD58 expression in cancer tissues was a powerful prognostic marker in male (p = 0.0474), pancreatic head carcinoma (p = 0.0002), histological G1–2 (p = 0.0113), tumor size > 4 cm (p = 0.0167), TNM stage IIB–III (p = 0.0027), lymph node metastasis-positive (p = 0.0014) and perineural invasion-positive group (p = 0.0398) (Fig. 5a–g, Table 3). This evidence concerns the gene CD58 and cancer.